Drug-loaded vascular stent and preparation method thereof

Abstract

The invention provides a drug-loading intravascular stent which comprises a stent body and a drug coating located on the stent, wherein the outer surface of stent coating is arranged as a smooth mirror surface; the coating comprises a first coating, a second coating and a third coating in turn from the surface of the stent body to the outer side; dopamine is used as a coating carrier of the first coating and is grafted with a substance A; PLGA is used as the coating carrier of the second coating; the second coating comprises a substance B; PLGA is used as the coating carrier of the third coating; the third coating comprises drugs C and B; A is heparin, B is sirolimus and C is curcumin. The invention also provides the preparation method for the stent. The method comprises the following steps: treating the stent; preparing a freeze-drying material; preparing the first coating; preparing the second coating; preparing the third coating. The invention has the advantages that three-layer drug loading coatings are arranged, the drugs are released layer by layer in the sequence of sirolimus, curcumin and heparin after the stent is implanted, the sequence is conformed to the occurrence trend of thrombus and smooth muscle proliferation, the effective drug duration is prolonged and the inhibiting effect for the subsequent potential thrombus and smooth muscle proliferation is achieved.

Description

technical field [0001] The invention relates to the field of cardiovascular technology, in particular to a drug-loaded vascular stent and a preparation method thereof. Background technique [0002] In-stent restenosis is a major problem in the application of vascular stents, and the restenosis rate is as high as 10-40% within one month after stent implantation. The implantation of vascular stents expands the stenotic diseased blood vessels, thereby expanding the lumen size of the blood vessels. The restenosis of the stent can be defined as the reduction of the lumen size after the blood vessel is expanded by the stent. The definition of restenosis in clinical use is mostly based on the results of angiography. During the follow-up after stent implantation, if the angiography examination confirms that the stenosis of the official lumen reaches 50% or more, it is usually considered as "restenosis". Restenosis considered by histopathology is defined from the perspective of tiss...

AI Technical Summary

Problems solved by technology

[0004] The drug-eluting stent currently used clinically has a short drug release period, and cannot treat multiple pathogenesis of restenosis at the same time, and has problems such as inflammation, calcification, late thrombosis, and insufficient anticoagulant performance. The poor binding force between the degradable polymer coating and the stent is easy to cause shedding, and the drug-loaded layer of the existing stent is out of sync with the pathological development of the affected area after the stent is implanted, so there are many unreasonable places

Images